Figure 2 from Deuterium Metabolic Imaging Differentiates Glioblastoma Metabolic Subtypes and Detects Early Response to Chemoradiotherapy
- Abstract:
- <p>Coil-localized <sup>2</sup>H MRS differentiates metabolic subtypes of GBM <i>in vivo</i>. <b>A-E,</b> Representative summed 5-minute <sup>2</sup>H spectra from tumor-free mice (<b>A</b>) and tumor-bearing mice with A11 (<b>B</b>), U87 (<b>C</b>), S2 (<b>D</b>), and AT5 tumors (<b>E</b>) acquired over a period of 60 minutes following an i.v. injection of 2 g/kg [6,6′-<sup>2</sup>H<sub>2</sub>]glucose. The summed spectra overlaid with the corresponding peak fits are shown. <b>F-I,</b> Concentrations of HDO (<b>F</b>), glucose (<b>G</b>), Glx (<b>H</b>), and lactate (<b>I</b>) determined from the fitted peaks in individual 5-minute spectra. <b>J-L,</b> The average concentrations of <sup>2</sup>H-labeled glucose (<b>J</b>), Glx (<b>K</b>), and lactate (<b>L</b>) measured between 20 and 65 minutes following injection of [6,6′-<sup>2</sup>H<sub>2</sub>] glucose in the four tumor models and in tumor-free animals. A one-way ANOVA showed that there were no significant differences in the labeled glucose concentration in the four tumor models and in tumor-free mice, but there were significant differences in the concentrations of labeled lactate and Glx between the glycolytic and mitochondrial subtype tumors and between the concentrations of labeled lactate in the glycolytic subtype tumors and the tumor-free animals. ns, not significant; *, <i>P</i> < 0.05; **, <i>P</i> < 0.01; ***, <i>P</i> < 0.001.</p>
- Authors:
- JCM Low, J Cao, F Hesse, AJ Wright, A Tsyben, I Alshamleh, R Mair, KM Brindle
- Publication date:
- 14th Jun 2024
- Full text
- DOI